Do analysts recommend LNAI or ALGS?

Aligos Therapeutics has a consensus target price of $38.50, suggesting a potential upside of 612.96%. Given Aligos Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Aligos Therapeutics is more favorable than Lunai Bioworks. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lunai Bioworks 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Aligos Therapeutics 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.86

Do analysts recommend LNAI or BYSI?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lunai Bioworks 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 BeyondSpring 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is LNAI or BYSI more profitable?

Company Net Margins Return on Equity Return on Assets Lunai Bioworks N/A N/A -1,617.76% BeyondSpring N/A N/A -28.88%

Do analysts rate LNAI or CNTX?

Context Therapeutics has a consensus price target of $6.17, suggesting a potential upside of 1,732.59%. Given Context Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Context Therapeutics is more favorable than Lunai Bioworks. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lunai Bioworks 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Context Therapeutics 1 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.67

Is LNAI or CNTX more profitable?

Lunai Bioworks' return on equity of 0.00% beat Context Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Lunai Bioworks N/A N/A -1,617.76% Context Therapeutics N/A -82.06% -72.74%

Do analysts recommend LNAI or QNCX?

Quince Therapeutics has a consensus target price of $206.71, indicating a potential upside of 635.64%. Given Quince Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Quince Therapeutics is more favorable than Lunai Bioworks. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lunai Bioworks 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Quince Therapeutics 2 Sell rating(s) 3 Hold rating(s) 6 Buy rating(s) 2 Strong Buy rating(s) 2.62

Is LNAI or QNCX more profitable?

Company Net Margins Return on Equity Return on Assets Lunai Bioworks N/A N/A -1,617.76% Quince Therapeutics N/A N/A -133.84%

Lunai Bioworks (LNAI) Competitors

$1.14 +0.01 (+0.44%)

As of 12:28 PM Eastern

Compare

LNAI vs. ALGS, BYSI, CNTX, QNCX, and SGMO

Should you buy Lunai Bioworks stock or one of its competitors? Lunai Bioworks's main competitors and comparable companies include Aligos Therapeutics (ALGS), BeyondSpring (BYSI), Context Therapeutics (CNTX), Quince Therapeutics (QNCX), and Sangamo Therapeutics (SGMO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Lunai Bioworks compare to Aligos Therapeutics?

Lunai Bioworks (NASDAQ:LNAI) and Aligos Therapeutics (NASDAQ:ALGS) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, earnings, risk, valuation, profitability, institutional ownership, dividends and analyst recommendations.

Aligos Therapeutics has higher revenue and earnings than Lunai Bioworks. Lunai Bioworks is trading at a lower price-to-earnings ratio than Aligos Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lunai Bioworks	$20.94K	246.81	-$178.01M	-$0.40	N/A
Aligos Therapeutics	$2.19M	15.39	-$24.19M	-$7.30	N/A

Lunai Bioworks has a net margin of 0.00% compared to Aligos Therapeutics' net margin of -241.01%. Lunai Bioworks' return on equity of 0.00% beat Aligos Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lunai Bioworks	N/A	N/A	-1,617.76%
Aligos Therapeutics	-241.01%	-160.72%	-92.30%

In the previous week, Aligos Therapeutics had 1 more articles in the media than Lunai Bioworks. MarketBeat recorded 1 mentions for Aligos Therapeutics and 0 mentions for Lunai Bioworks. Lunai Bioworks' average media sentiment score of 0.00 equaled Aligos Therapeutics'average media sentiment score.

Company	Overall Sentiment
Lunai Bioworks	Neutral
Aligos Therapeutics	Neutral

Lunai Bioworks has a beta of 0.37, suggesting that its share price is 63% less volatile than the broader market. Comparatively, Aligos Therapeutics has a beta of 2.36, suggesting that its share price is 136% more volatile than the broader market.

71.4% of Lunai Bioworks shares are owned by institutional investors. Comparatively, 60.4% of Aligos Therapeutics shares are owned by institutional investors. 0.5% of Lunai Bioworks shares are owned by insiders. Comparatively, 7.8% of Aligos Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Aligos Therapeutics has a consensus target price of $38.50, suggesting a potential upside of 612.96%. Given Aligos Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Aligos Therapeutics is more favorable than Lunai Bioworks.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lunai Bioworks	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Aligos Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

Summary

Aligos Therapeutics beats Lunai Bioworks on 11 of the 16 factors compared between the two stocks.

How does Lunai Bioworks compare to BeyondSpring?

Lunai Bioworks (NASDAQ:LNAI) and BeyondSpring (NASDAQ:BYSI) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, media sentiment, valuation, profitability, dividends and institutional ownership.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lunai Bioworks	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
BeyondSpring	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Lunai Bioworks has a beta of 0.37, suggesting that its stock price is 63% less volatile than the broader market. Comparatively, BeyondSpring has a beta of -0.21, suggesting that its stock price is 121% less volatile than the broader market.

In the previous week, BeyondSpring had 7 more articles in the media than Lunai Bioworks. MarketBeat recorded 7 mentions for BeyondSpring and 0 mentions for Lunai Bioworks. BeyondSpring's average media sentiment score of 0.11 beat Lunai Bioworks' score of 0.00 indicating that BeyondSpring is being referred to more favorably in the news media.

Company	Overall Sentiment
Lunai Bioworks	Neutral
BeyondSpring	Neutral

71.4% of Lunai Bioworks shares are held by institutional investors. Comparatively, 40.3% of BeyondSpring shares are held by institutional investors. 0.5% of Lunai Bioworks shares are held by insiders. Comparatively, 29.3% of BeyondSpring shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Company	Net Margins	Return on Equity	Return on Assets
Lunai Bioworks	N/A	N/A	-1,617.76%
BeyondSpring	N/A	N/A	-28.88%

BeyondSpring has higher revenue and earnings than Lunai Bioworks. BeyondSpring is trading at a lower price-to-earnings ratio than Lunai Bioworks, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lunai Bioworks	$20.94K	246.81	-$178.01M	-$0.40	N/A
BeyondSpring	$1.75M	18.47	-$1.01M	-$0.12	N/A

Summary

BeyondSpring beats Lunai Bioworks on 7 of the 11 factors compared between the two stocks.

How does Lunai Bioworks compare to Context Therapeutics?

Lunai Bioworks (NASDAQ:LNAI) and Context Therapeutics (NASDAQ:CNTX) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, earnings, risk, analyst recommendations, valuation and institutional ownership.

Context Therapeutics has a consensus price target of $6.17, suggesting a potential upside of 1,732.59%. Given Context Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Context Therapeutics is more favorable than Lunai Bioworks.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lunai Bioworks	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Context Therapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

Lunai Bioworks' return on equity of 0.00% beat Context Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lunai Bioworks	N/A	N/A	-1,617.76%
Context Therapeutics	N/A	-82.06%	-72.74%

Lunai Bioworks has a beta of 0.37, suggesting that its stock price is 63% less volatile than the broader market. Comparatively, Context Therapeutics has a beta of 1.71, suggesting that its stock price is 71% more volatile than the broader market.

71.4% of Lunai Bioworks shares are held by institutional investors. Comparatively, 14.0% of Context Therapeutics shares are held by institutional investors. 0.5% of Lunai Bioworks shares are held by insiders. Comparatively, 4.8% of Context Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Context Therapeutics has lower revenue, but higher earnings than Lunai Bioworks. Lunai Bioworks is trading at a lower price-to-earnings ratio than Context Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lunai Bioworks	$20.94K	246.81	-$178.01M	-$0.40	N/A
Context Therapeutics	N/A	N/A	-$36.12M	-$0.48	N/A

In the previous week, Lunai Bioworks' average media sentiment score of 0.00 equaled Context Therapeutics'average media sentiment score.

Company	Overall Sentiment
Lunai Bioworks	Neutral
Context Therapeutics	Neutral

Summary

Context Therapeutics beats Lunai Bioworks on 8 of the 12 factors compared between the two stocks.

How does Lunai Bioworks compare to Quince Therapeutics?

Lunai Bioworks (NASDAQ:LNAI) and Quince Therapeutics (NASDAQ:QNCX) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, institutional ownership, valuation, risk, analyst recommendations, profitability, dividends and earnings.

Lunai Bioworks has a beta of 0.37, indicating that its share price is 63% less volatile than the broader market. Comparatively, Quince Therapeutics has a beta of 1.33, indicating that its share price is 33% more volatile than the broader market.

Quince Therapeutics has lower revenue, but higher earnings than Lunai Bioworks. Lunai Bioworks is trading at a lower price-to-earnings ratio than Quince Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lunai Bioworks	$20.94K	246.81	-$178.01M	-$0.40	N/A
Quince Therapeutics	N/A	N/A	-$83.98M	-$156.71	N/A

Company	Net Margins	Return on Equity	Return on Assets
Lunai Bioworks	N/A	N/A	-1,617.76%
Quince Therapeutics	N/A	N/A	-133.84%

Quince Therapeutics has a consensus target price of $206.71, indicating a potential upside of 635.64%. Given Quince Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Quince Therapeutics is more favorable than Lunai Bioworks.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lunai Bioworks	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Quince Therapeutics	2 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.62

In the previous week, Quince Therapeutics had 4 more articles in the media than Lunai Bioworks. MarketBeat recorded 4 mentions for Quince Therapeutics and 0 mentions for Lunai Bioworks. Quince Therapeutics' average media sentiment score of 0.67 beat Lunai Bioworks' score of 0.00 indicating that Quince Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Lunai Bioworks	Neutral
Quince Therapeutics	Positive

71.4% of Lunai Bioworks shares are owned by institutional investors. Comparatively, 30.8% of Quince Therapeutics shares are owned by institutional investors. 0.5% of Lunai Bioworks shares are owned by insiders. Comparatively, 5.6% of Quince Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Quince Therapeutics beats Lunai Bioworks on 11 of the 14 factors compared between the two stocks.

How does Lunai Bioworks compare to Sangamo Therapeutics?

Sangamo Therapeutics (NASDAQ:SGMO) and Lunai Bioworks (NASDAQ:LNAI) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, media sentiment, valuation, institutional ownership, earnings, profitability, risk and analyst recommendations.

Sangamo Therapeutics currently has a consensus target price of $5.50, indicating a potential upside of 7,332.43%. Given Sangamo Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Sangamo Therapeutics is more favorable than Lunai Bioworks.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sangamo Therapeutics	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75
Lunai Bioworks	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Sangamo Therapeutics has a beta of 1.3, suggesting that its share price is 30% more volatile than the broader market. Comparatively, Lunai Bioworks has a beta of 0.37, suggesting that its share price is 63% less volatile than the broader market.

Sangamo Therapeutics has higher revenue and earnings than Lunai Bioworks. Lunai Bioworks is trading at a lower price-to-earnings ratio than Sangamo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sangamo Therapeutics	$39.55M	0.78	-$122.93M	-$0.38	N/A
Lunai Bioworks	$20.94K	246.81	-$178.01M	-$0.40	N/A

Lunai Bioworks has a net margin of 0.00% compared to Sangamo Therapeutics' net margin of -310.81%. Lunai Bioworks' return on equity of 0.00% beat Sangamo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sangamo Therapeutics	-310.81%	-2,662.06%	-132.12%
Lunai Bioworks	N/A	N/A	-1,617.76%

In the previous week, Sangamo Therapeutics' average media sentiment score of 0.00 equaled Lunai Bioworks'average media sentiment score.

Company	Overall Sentiment
Sangamo Therapeutics	Neutral
Lunai Bioworks	Neutral

56.9% of Sangamo Therapeutics shares are held by institutional investors. Comparatively, 71.4% of Lunai Bioworks shares are held by institutional investors. 4.1% of Sangamo Therapeutics shares are held by insiders. Comparatively, 0.5% of Lunai Bioworks shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Sangamo Therapeutics beats Lunai Bioworks on 10 of the 14 factors compared between the two stocks.

Get Lunai Bioworks News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LNAI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LNAI vs. The Competition

Export

Metric	Lunai Bioworks	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$5.19M	$3.86B	$7.17B	$13.47B
Dividend Yield	N/A	3.65%	2.54%	17.38%
P/E Ratio	-2.86	13.32	274.36	26.32
Price / Sales	247.90	1,233.28	599.51	86.61
Price / Cash	N/A	39.04	27.22	34.70
Price / Book	-0.12	16.55	11.02	6.40
Net Income	-$178.01M	-$23.20M	$3.50B	$381.19M
7 Day Performance	-35.31%	-2.98%	-1.69%	-0.10%
1 Month Performance	-52.09%	-11.11%	-6.40%	-4.32%
1 Year Performance	-88.73%	15.89%	6.47%	1.86%

Lunai Bioworks Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LNAI Lunai Bioworks	0.5438 of 5 stars	$1.15 +0.4%	N/A	-89.0%	$5.19M	$20.94K	N/A	29
ALGS Aligos Therapeutics	1.9104 of 5 stars	$5.51 -0.7%	$38.50 +598.7%	-46.4%	$34.41M	$31.52M	N/A	82	News Coverage Positive News
BYSI BeyondSpring	0.1748 of 5 stars	$0.78 +7.2%	N/A	-55.1%	$31.96M	N/A	N/A	44	News Coverage Gap Down
CNTX Context Therapeutics	2.1062 of 5 stars	$0.35 -6.8%	$6.17 +1,683.8%	-69.4%	$31.76M	N/A	N/A	15
QNCX Quince Therapeutics	3.4851 of 5 stars	$31.00 +3.3%	$206.71 +566.8%	-91.5%	$31.53M	N/A	N/A	38

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LNAI) was last updated on 10/6/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Lunai Bioworks (LNAI) Competitors

LNAI vs. ALGS, BYSI, CNTX, QNCX, and SGMO

How does Lunai Bioworks compare to Aligos Therapeutics?

Summary

How does Lunai Bioworks compare to BeyondSpring?

Summary

How does Lunai Bioworks compare to Context Therapeutics?

Summary

How does Lunai Bioworks compare to Quince Therapeutics?

Summary

How does Lunai Bioworks compare to Sangamo Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LNAI vs. The Competition

Lunai Bioworks Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Lunai Bioworks (LNAI) Competitors

LNAI vs. ALGS, BYSI, CNTX, QNCX, and SGMO

How does Lunai Bioworks compare to Aligos Therapeutics?

Which has preferable valuation and earnings, LNAI or ALGS?

Is LNAI or ALGS more profitable?

Does the media refer more to LNAI or ALGS?

Which has more volatility and risk, LNAI or ALGS?

Do institutionals and insiders hold more shares of LNAI or ALGS?

Do analysts recommend LNAI or ALGS?

Summary

How does Lunai Bioworks compare to BeyondSpring?

Do analysts recommend LNAI or BYSI?

Which has more volatility & risk, LNAI or BYSI?

Does the media prefer LNAI or BYSI?

Do insiders & institutionals have more ownership in LNAI or BYSI?

Is LNAI or BYSI more profitable?

Which has better earnings and valuation, LNAI or BYSI?

Summary

How does Lunai Bioworks compare to Context Therapeutics?

Do analysts rate LNAI or CNTX?

Is LNAI or CNTX more profitable?

Which has more risk and volatility, LNAI or CNTX?

Do insiders and institutionals have more ownership in LNAI or CNTX?

Which has better valuation & earnings, LNAI or CNTX?

Does the media favor LNAI or CNTX?

Summary

How does Lunai Bioworks compare to Quince Therapeutics?

Which has more risk & volatility, LNAI or QNCX?

Which has stronger earnings & valuation, LNAI or QNCX?

Is LNAI or QNCX more profitable?

Do analysts recommend LNAI or QNCX?

Does the media favor LNAI or QNCX?

Do institutionals and insiders have more ownership in LNAI or QNCX?

Summary

How does Lunai Bioworks compare to Sangamo Therapeutics?

Do analysts prefer SGMO or LNAI?

Which has more volatility and risk, SGMO or LNAI?

Which has higher earnings & valuation, SGMO or LNAI?

Is SGMO or LNAI more profitable?

Does the media refer more to SGMO or LNAI?

Do insiders and institutionals believe in SGMO or LNAI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LNAI vs. The Competition

Lunai Bioworks Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools